Clinical Trial Update: Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of Silevertinib (BDTX-1535) in glioblastoma and EGFR-mutant non-small cell lung cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Silevertinib

Snippet

Sponsor: Black Diamond Therapeutics, Inc. | Conditions: Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING